Epitope mapping Flashcards

1
Q

Using examples explain the difference between linear and conformational epitopes

A

Epitopes are molecular structures on an antigen that make direct contact with the antibody, made of amino acids or protein sequences. They can be linear consisting of amino acid sequences which can be directly identified by antibodies or conformational which require specific 3d folding to be recognised by the antibody or receptor

Linear - CD20 epitopes which Rituximab and Ofatumumab monoclonal antibodies act against.

Confirmational - HIV contains confirmation epitopes as the glycoproteins gp41 and gp120 require specific calibration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Describe approaches to map epitopes using X-ray crystallography.

A

Initiatlly a pure crystal is obtained of the epitope using crystallization, this is then flash frozen preserving crystals.
the crystal is exposed to a beam of x-rays which interact with the electron density of the crystal lattice causing a refraction pattern detected by a specialised camera. By analysing the diffraction pattern and electron density overlayed the structure of the crystal the positions of the atoms are obtained and the epitope position can be obtained.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Describe approaches to map epitopes using cryogenic EM.

A

In this approach, purified protein samples are flash-frozen and imaged using an electron microscope. The resulting images are processed to generate a three-dimensional reconstruction of the protein structure. To map epitopes,

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Describe the principle to map epitopes using peptide scans

A

peptide library is designed to cover the entire sequence of the protein of interest. Typically, short peptides with a length of 10-20 amino acids are used.

The peptides in the library are designed to overlap with neighboring peptides by a fixed number of amino acids.

The peptide library is tested for binding to the target antibodies or receptors using an appropriate binding assay, such as enzyme-linked immunosorbent assay (ELISA).

The peptides that show binding to the antibodies or receptors are identified as potential epitopes by m measuring signal intensity.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Explain the principle of fine mapping in epitope mapping

A

Fine mapping aims to narrow down the epitope region to a smaller segment and pinpoint the key residues responsible for binding through the substitution of singular amino acid residues.

Alanine scanning involves systematically substituting each amino acid within the epitope region with alanine (or sometimes glycine) while keeping the rest of the protein sequence intact. The mutated peptides are then tested for their ability to bind to the antibodies or receptors.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Explain how you would use Array-based oligo-peptide scanning to do epitope mapping.

A

Design a library of short peptides that covers the entire protein sequence or a specific region of interest. The peptides are typically around 10-20 amino acids in length.

Synthesize the peptides directly on the surface of an array, such as a glass slide or a microplate.

ncubate the peptide array with the target antibodies or receptors of interest. The antibodies or receptors can be labeled with a fluorescent or enzyme tag for detection.

detection methods such as fluorescence imaging, enzyme-linked detection, or mass spectrometry to identify the bound antibodies or receptors.

This can then be followed by fine mapping techniques for validation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Explain how you would use Array-based oligo-peptide scanning to do epitope mapping.

A

Design a library of short peptides that covers the entire protein sequence or a specific region of interest. The peptides are typically around 10-20 amino acids in length.

Synthesize the peptides directly on the surface of an array, such as a glass slide or a microplate.

ncubate the peptide array with the target antibodies or receptors of interest. The antibodies or receptors can be labeled with a fluorescent or enzyme tag for detection.

detection methods such as fluorescence imaging, enzyme-linked detection, or mass spectrometry to identify the bound antibodies or receptors.

This can then be followed by fine mapping techniques for validation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the difference between continuous and discontinuous epitopes?

A

Continous or linear epitopes consist of amino acid sequences directly next to each other however discontinuous require 3d configuration / folding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Describe The principle of chemiluminescence-based epitope mapping

A

The target antigen, which contains the epitope of interest, is immobilized onto a solid support, such as a membrane or a microplate. The immobilization can be achieved through various methods, such as covalent binding or passive adsorption.

A specific antibody that recognizes and binds to the antigen is incubated with the immobilized antigen. The antibody is usually conjugated with an enzyme, such as horseradish peroxidase (HRP), that can catalyze a chemiluminescent reaction.

A chemiluminescent substrate specific to the enzyme conjugated to the antibody is added to the system. The substrate typically consists of a luminol derivative that, upon enzymatic reaction, produces light.

he enzyme conjugated to the antibody catalyzes the oxidation of the chemiluminescent substrate, resulting in the generation of excited intermediates. As these intermediates decay to the ground state, they emit photons of light, producing a detectable chemiluminescent signal.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What was the objective of creating B cells hybridomas in the practical?

A

We want to produce immortal and high replicating B cells to be antibody factories

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What was the principle of the B cell hybridomas test explaining the use of HAT medium.

A

We need immortal and high replication B cells to produce Mab which B cells cannot do so to achieve this we:

Immunised rats with CD20 B cells, these cells are then fused with myeloma cells to create hybridomas.

These cells are then Cultured in HAT medium- (hypoxanthine-aminopterin-thymidine ) Aminopterin present in HAT media blocks the power of cells to synthesize nucleotides by the de novo synthesis pathway.

Hypoxanthine and deoxythymidine allow cells with functional hypoxanthine-guanine phosphoribosyltransferase (HGPRT) genes to survive through salvage pathways (hybridomas) . Due to a limited life span, unfused B cells perish within a few days. Unfused malignant neoplastic cells die as a result of the lack of the hypoxanthine-guanine phosphoribosyltransferase (HGPRT) gene.

Finally harvest Mab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is CD20 and what is its role in B cells.

A

Cultural differentiation 20 CD20 is a membrane-embedded surface molecule which plays a role in the development and differentiation of B cells into plasma cells

CD20 is seen more in mature b cells.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Explain the principle of CLIPS - chemical linkage of peptides onto scaffolding.

A

The addition of chemicals such as cl- or br- to forum bonds and folds within AA to aid in epitope mapping of confirmation structures

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What Mab are clinically trailed for Covid ?

A

COV 1/2 - Strovimab
REGEN COV 2 - Casirivimab & imdevimab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

How does Mab effect bacterial infections?

A

Neutralising toxins and antibodies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What Mab are clinically trailed for Ebola?

A

Zmapp - plant Mab
Ebanga
Inmazeb

17
Q

What is the cause of epitope variability in HIV?

A

HIV contains reverse transcriptase instead of RNA polymerase which does not have a proof reading function which means errors are not corrected leading to mutations and more variability in the genome of HIV that Covid.

18
Q

What are the epitope regions in HIV?

A

V3 Loop Epitope: Located in the third variable loop of the HIV envelope glycoprotein gp120, this epitope is a target for neutralizing antibodies. It is highly variable and plays a crucial role in viral entry into host cells.

gp41 Epitopes: The transmembrane glycoprotein gp41 contains several linear epitopes that are recognized by antibodies. These include the immunodominant epitope recognized by the 2F5 and 4E10 antibodies, which target the membrane-proximal external region (MPER) of gp41.

p24 Epitopes: The p24 protein, also known as the capsid protein, contains linear epitopes that are recognized by antibodies during HIV infection. These epitopes are often used as targets for diagnostic tests to detect the presence of HIV antibodies.

CD4 Binding Site: The CD4 binding site is a conformational epitope located on the gp120 protein. It is recognized by antibodies that inhibit the binding of HIV to the CD4 receptor on host cells, thereby blocking viral entry.

Membrane Proximal External Region (MPER): As mentioned earlier, the MPER of gp41 contains conformational epitopes that are targets for broadly neutralizing antibodies, such as 2F5 and 4E10.

19
Q

Describe the immune response to HIV with mention of specific antibodies?

A

The acute immune reponse e recognizes the presence of the virus through pattern recognition receptors (PRRs) on immune cells, such as dendritic cells and macrophages.

Infected dendritic cells capture viral particles and present HIV antigens to CD4+ T cells. This interaction triggers the activation of CD4+ T cells, leading to their proliferation and differentiation into different subsets.

Initally gp41 IgM, then gp41 IgM,
Gag IgG, v3 gp120, CD4b3 lastly ADcc abs. this enbds the acute response.

Antibodies with high effect are created in the chronic stage due to affinity maturation through receptor editing.

release of MPER IgG this determines HIV progressors or controllers.

20
Q

What is HIV receptor and how antibodies effect this.

A

HIV binds to CD4 antigen and antibodies block this binding.
Additionally antibodies block co reptor, facilitate compliment dependant lysis, aid agglutination.

21
Q

How does HIV protect itself from antibodies?

A
  1. Variable antigens
  2. Sugar coating as sugar has low immunogencity hides from immune system.
  3. Sends decoy envelope proteins so immune response is gathered elsewhere
    4 Use of confirmation epitopes gp41 and gp120
  4. gp are spread out
  5. Steric occlusion - non binding interactions effect binding sites
22
Q

What is the function of Hela cells for Hela cells in screening for HIV.

A

They act as reporter cells that overexpress CD4 and CCRS, if HIV contacts the cells they turn blue which shows neutralisation did not work for that antibody.

23
Q

What is Ebolas pathogenesis?

A

Initally it interfers with interferon signalling stopping antiviral progression.

Once macrophages recognise the virus a cytokine storm develops which causes inflammation and damage to the blood vessels.

NK killer cells lyse effected cells releasing cytotoxic chemicals damaging tissues

Neutreophills self destruct caused by cytokines which releases cytotoxic chemicals

Dendritic cells do not mature well due to no interferon

24
Q

Explain the ZMAPP mab and its related disease.

A

ZMAPP is a Mab that acts on Ebola, it is isolated from mice with Ebola virus and chimerized into human IgG scaffolding.

Bacteria containing this is used to infect tobacco plants creating large scale production of antibodies through plants.

It showed efficacy in primates but not humans.

25
Q

Explain SARS-cov-2 entrance into cells.

A

The viron is coated in spike protein and is originally not active. Once the viron comes into contact with its ACE2 receptor it needs the action of a type II transmembrane serine protease to become active and fuse into the cell.

26
Q

What mab is approved for SARS-COV-2 and how do they function.

A

REGEN- COV
SORTORVIMAB

These upregulate phagocytosis, antibody dependant cellular cytotoxicity